In vitro-in vivo correlation of modified release dosage form of lamotrigine

Biopharmaceutics and Drug Disposition

Volumn 30, Issue 9, 2009, Pages 524-531

  Shah, Hiten J ^a,b   Subbaiah, Gunta ^a   Patel, Dasharath M ^b   Patel, Chhagan N ^b  

^a Torrent Pharmaceuticals Ltd   (India)

^b Shri Sarvajanik Pharmacy College   (India)

Author keywords

IVIVC; Lamotrigine; Modified release dosage form

Indexed keywords

LAMOTRIGINE;

ADULT; ARTICLE; CALCULATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; NORMAL HUMAN; PREDICTION; TABLET FORMULATION; VOLUNTEER;

ADULT; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; HUMANS; MALE; SOLUBILITY; TABLETS; TRIAZINES;

EID: 73349127074     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.688     Document Type: Article

References (29)

1. Fitton A, Goa KL. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs 1995; 50: 691-713.
2. Schachter SC, Leppik E, Matsuo F, et al. Lamotrigine: a six month, placebo-controlled, safety and tolerance study. J Epilepsy 1995; 8: 201-209.
3. Messenheimer J, Ramsay R, Willmore L, et al. Lamotrigine therapy for partial seizures: a multi-center placebo-controlled, double-blind cross-over trial. Epilepsia 1994; 35: 113-121.
4. Chang G, Vasquez B, Gilliam F, et al. Lamictal (lamotrigine) monotherapy is an effective treatment for partial seizures (abstract). Neurology 1997; 48: A335.
5. Brodie M, Richens A, Yuen A. Lamotrigine/ carbamazepine, monotherapy trial group: double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476-479.
6. Matsuo F, Bergen D, Faught E, et al. Lamotrigine protocol 05 clinical trial group: placebo-controlled study of the efficacy and safety of lamotrigine in patient with partial seizures. Neurology 1993; 43: 2284-2291.
7. McGeer EG, Zhu SG. Lamotrigine protects against kainate but not ibotenate lesions in rat striatum. Neurosci Lett 1990; 112: 348-351.
8. Rataud J, Debarnot F, Mary V, Pratt J, Stutzmann JM. Comparative study of voltage sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents. Neurosci Lett 1994; 172: 19-23.
9. Smith SE, Meldrum BS. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 1995; 26: 117-121.
10. Crumrine RC, Bergstrand K, Cooper AT, Faison WL, Cooper BR. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. Stroke 1997; 28: 2230-2236.
11. Wiard RP, Dickerson MC, Beek O, Norton R, Cooper BR. Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model cerebral ischemia. Stroke 1995; 26: 446-472.
12. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM. Lamotrigine: A review of its use in bipolar disorder. Drugs 2003; 63: 2029-2050.
13. Physical Desk Reference. 2007; 61: 1481-1490.
14. Binnie CD, Beintema DJ, Debets RMC, et al. Seven day administration of lamotrigine in epilepsy: placebo controlled add-on trial. Epilepsy Res 1987; 1: 202-208. DOI: 10.1016/0920-1211(87)90042-8.
15. Sun Y, Peng Y, Chen Y, Shukla AJ. Application of artificial neural networks in the design of controlled release drug delivery system. Adv Drug Del Rev 2003; 55: 1201-1215. DOI: 10.1016/S0169-409X(03)00119-4.
16. Guidance for Industry. Extended Release Oral Dosage Forms: Development, Evaluation and Application of In Vitro/In Vivo Correlation. U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research: Rockville, MD; September 1997.
17. Guidance for Industry. SUPAC-MR: Modified Release Solid Oral Dosage Forms, Scale-Up and Post Approval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research: Rockville, MD; September 1997.
18. Note for Guidance on Quality of Modified Release Oral and Transdermal Dosage Forms: Section II (Pharmacokinetic and Clinical Evaluation). The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products: London, UK; CPMP/EWP/280/96; July 1999.
19. Note for Guidance Development Pharmaceutics. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products: London, UK; CPMP/QWP/155/96; January 1998.
20. ICH Harmonised Tripartite Guideline. Pharmaceutical Development Q8, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 10 November 2005.
21. FDA Guidance for Industry. Bioavailability Studies for Orally Administered Drug- Products- General Considerations. Center for Drug Evaluation and Research, US Department of Health and Human Services, 2000.
22. Shah HJ, Subbaiah G, Patel DM, Suhagia BN, Patel CN. Rapid quantification of lamotrigine in human plasma by two liquid chromatographic systems connected with a tandem mass spectrometry. J Chromatogr Sci, article in press.
23. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. BI Waverly Pvt Ltd: New Delhi, 1996; 469-472.
24. Kortejarvi H, Mikkola J, Backman M, Antila S, Marvola M. Development of level A, B and C in vitro-in vivo correlations for modified release levosimendan capsules. Int J Pharm 2002; 241: 87-95.
25. Turner S, Federice C, Hite M, Fassihi R. Formulation development and human in vitro in vivo correlation for a novel, monolithic controlled release matrix system of high load and high water soluble drug niacin. Drug Dev Ind Pharm 2004; 30: 797-807.
26. Rao BS, Seshasayana A, Saradhi SVP. Correlation of in vitro release and in vivo absorption characteristics of rifampicin from ethylcellulose coated nonpareil beads. Int J Pharm 2001; 230: 1-9.
27. Parojcic J, Ibric S, Djuric Z, Jovanovic M, Corrigan OI. An investigation into the usefulness of generalized regression neural network analysis in the development of level A in vitro-in vivo correlation. Eur J Pharm Sci 2007; 30: 264-272.
28. Dunne A, O'Hare T, Devane J. Level A in vivo-in vitro correlation: nonlinear models and statistical methodology. J Pharm Sci 1997; 86: 1245-1249.
29. Modi NB. In vitro-in vivo correlation. In Pharmaceutical Product Development In Vitro-In Vivo Correlation, Chilukuri DM, Sunkara G, Young D (eds). Informa Healthcare: New York, 2007; 107-123.